Fresenius Medical Care stock holds steady as mid-2026 trading data align with recent NYSE levels.
Published on 08/19/2026 at 17:26 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS
Fresenius Medical Care AG & Co. KGaA (ISIN DE0005785802) stock is showing a steady trading profile in mid-August 2026, with recent prices on the New York Stock Exchange and CBOE quotes giving investors a clear benchmark for assessing the shares.
Recent price levels and market context
Recent reporting on Fresenius Medical Care stock indicates that the shares most recently closed at $23.75 on the New York Stock Exchange on August 14, 2026, providing a concrete price reference just days before August 19, 2026. This closing level anchors the current valuation context for the ADR listed under the FMS ticker, allowing investors to compare subsequent intraday and short-term moves against a known baseline.
The same coverage cites a later reference quote of $23.54 for Fresenius Medical Care stock as of August 17, 2026, at 3:58 p.m. Eastern Time, representing a 0.97 percent intraday decline from a previous close of $23.77. That small change illustrates a modest softening within a narrow trading corridor, but not a broad selloff, and underscores that the shares have stayed within a tight band across several sessions in mid-August 2026.
Market data compiled on CBOE also point to a price level of $23.56 for Fresenius Medical Care stock as of August 18, 2026, with a five day change of 0.21 percent and a year to date change of minus 1.38 percent. Together, these figures show that the shares have delivered only a small positive move over the past trading week while remaining slightly negative since the start of 2026, a pattern that aligns with the stable trading range implied by the NYSE closing and reference quotes.
In addition, shareholder structure information from a recent overview notes Fresenius SE & Co. KGaA as holding 30.39 percent of Fresenius Medical Care. This substantial stake highlights the continued strategic importance of the dialysis provider within the broader Fresenius group and helps explain why both entities tend to be evaluated together when investors consider exposure to global health care services and products.
Mid-2026 performance signals and comparison
Looking more closely at the short term performance, the combination of the August 14, 2026 closing price of $23.75, the August 17, 2026 intraday quote of $23.54, and the CBOE price of $23.56 as of August 18, 2026 suggests that daily moves in Fresenius Medical Care stock have generally remained within a band of less than $0.25 across several sessions. For investors, that narrow price dispersion under one percent per day indicates a muted volatility phase rather than an aggressive trend phase, which can matter for position sizing and risk management.
From a year to date perspective, the minus 1.38 percent change reported for Fresenius Medical Care stock as of August 18, 2026, implies that the shares are trading slightly below their level at the start of 2026. While this is not a dramatic drawdown, it does mean that any dividend payments or incremental earnings improvements would need to be considered when evaluating total return over the period, especially given the broadly steady price pattern in recent weeks.
The positive five day change of 0.21 percent as of August 18, 2026 when set against the year to date decline provides a small but meaningful contrast. Short term trading has delivered a marginal gain over the most recent week, even as the longer horizon remains mildly negative. This combination can be interpreted as a sign that market participants are not aggressively revaluing Fresenius Medical Care in either direction, but are willing to nudge the shares higher on incremental news and broader sector moves.
For context, the parent company Fresenius SE & Co. KGaA is reported at 46.72 EUR on CBOE in mid August 2026 with a five day change of minus 0.37 percent and a year to date change of minus 2.05 percent. This comparison reveals that while the parent has experienced a slightly larger negative shift since the beginning of the year, Fresenius Medical Care stock has held closer to flat year to date, suggesting a somewhat more resilient performance for the dialysis business relative to the wider Fresenius group over this particular period.
Product and business model: renal care services
Fresenius Medical Care AG & Co. KGaA is globally known for providing dialysis services and products for patients with chronic kidney failure, operating an extensive network of dialysis clinics and manufacturing related equipment and supplies. Its business model combines recurring treatment revenue from long term patient relationships with sales of dialysis machines, filters, and consumables, making the company heavily exposed to trends in renal care demand, reimbursement frameworks, and clinical practice standards.
Within that framework, the core product offering remains dialysis treatment services delivered through Fresenius Medical Care clinics and centers across multiple regions. These services typically involve periodic hemodialysis sessions for patients with end stage renal disease and require specialized equipment and trained staff. The combination of stable patient volumes and regulated reimbursement structures tends to create relatively predictable revenue streams, which can help support the kind of moderate volatility profile currently visible in the mid August 2026 trading data for Fresenius Medical Care stock.
Closing view on Fresenius Medical Care stock
As of the most recent confirmed data around August 18, 2026, Fresenius Medical Care stock was quoted at $23.56 on CBOE, with a five day gain of 0.21 percent and a year to date performance of minus 1.38 percent. These figures, together with the August 14, 2026 New York Stock Exchange close of $23.75 and the August 17, 2026 intraday quote of $23.54, frame a trading picture in which the shares have moved only modestly, offering investors a relatively stable price environment in which fundamentals and longer term dialysis demand trends can be assessed without the distraction of sharp daily swings.
Fact box
Company: Fresenius Medical Care AG & Co. KGaA
ISIN: DE0005785802
Ticker: FMS
Exchange: New York Stock Exchange (ADR), CBOE quote reference
Price (as of August 18, 2026, 3:59 p.m. ET): $23.56 USD
Market cap: not specified in the cited market data
Sector / Industry: Health care equipment and services, renal care
Index membership: not specified in the cited market data
Investor Relations
Further details on Fresenius Medical Care AG & Co. KGaA can be found via the company's investor relations website, which provides additional information on strategy, operations, and financial reporting.
